A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)

Trial Profile

A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 May 2015

At a glance

  • Drugs Flurpiridaz F 18 (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use; Registrational
  • Sponsors Lantheus Medical Imaging
  • Most Recent Events

    • 04 May 2015 Based on results of the first phase III trial, Lantheus will conduct a new second phase III trial with a redesigned protocol and different primary endpoints, according to a media release.
    • 19 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top